Dermata Therapeutics, Inc. (DRMA) Stock Overview
Explore Dermata Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Dermata Therapeutics, Inc. (DRMA)
Key Financials
Key Financials
Market Cap
811.1K
P/E Ratio
-0.65
EPS (TTM)
$-4.17
ROE
-1.28%
DRMA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Dermata Therapeutics, Inc. (DRMA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 46.51, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.65 and a market capitalization of 811.1K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.